Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern Time

Rhea-AI Summary

Lantheus Holdings (NASDAQ: LNTH) announced a conference call scheduled for November 4, 2021, at 8:00 a.m. ET to discuss its Q3 2021 financial and operating results. Investors can access the call by dialing 1-866-498-8390 for U.S. callers or 1-678-509-7599 for international callers, using passcode 6775813. A live webcast will also be available on the company's website. The call will provide insights into Lantheus's innovative imaging diagnostics and therapeutic solutions, including products like PYLARIFY^® and RELISTOR^®.

Positive

• Upcoming conference call could provide meaningful insights into financial performance.
• Lantheus is recognized as a leader in imaging diagnostics and therapeutics.

Negative

• None.

NORTH BILLERICA, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021, to discuss its financial and operating results for the third quarter of 2021.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 6775813. A live webcast will also be available in the Investors section of the Company’s website at www.lantheus.com.

A replay of the webcast will be available in the Investors section of the Company’s website approximately two hours after completion of the call and will be archived for 30 days.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow^® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY^®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite^® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA^® for the treatment of certain rare neuroendocrine tumors; and RELISTOR^® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

Contacts:

Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Director, Corporate Communications
646-975-2533
media@lantheus.com

FAQ

When will Lantheus Holdings discuss its Q3 2021 financial results?

Lantheus Holdings will discuss its Q3 2021 financial results on November 4, 2021, at 8:00 a.m. ET.

How can I access the Lantheus Holdings conference call?

You can access the conference call by dialing 1-866-498-8390 for U.S. callers or 1-678-509-7599 for international callers, with passcode 6775813.

Where can I find the webcast of the Lantheus Holdings conference call?

The live webcast will be available in the Investors section of the Lantheus Holdings website.

What are some key products offered by Lantheus Holdings?

Lantheus Holdings offers products like PYLARIFY^® for prostate cancer imaging and RELISTOR^® for treating opioid-induced constipation.